tbuckley/cabot-search huggingface dataset:
Abstract 3550: Benefits of follow-up screening for Epstein Barr virus DNA in patients with localized nasopharyngial carcinoma .
Authors: Cheng-Lung Hsu
Journal: Cancer Research (2013)

Abstract Objective: In this study, we investigated whether detection of Epstein Barr virus (EBV)-DNA in plasma is a prognostic indicator of disease recurrence in patients who have been treated for localized nasopharyngeal carcinoma. Methods: Study subjects comprised 389 patients who had received treatment for localized nasopharyngeal carcinoma in our outpatient department. Copy numbers of EBV-DNA in plasma were assessed by real-time quantitative PCR. Patients in whom disease recurrence was suspected underwent positron emission tomography (PET) imaging studies. Results: Plasma EBV-DNA was detectable in 60 of 63 (95%) patients with metastatic disease and all had positive PET findings. In addition, of the 45 patients with localized recurrent disease, plasma EBV-DNA was detectable in 23 (51%) patients and positive PET scan results were obtained in 40 (89%) of the patients. Of the 284 patients who were disease free, plasma EBV-DNA was detected in 90 (32%) patients. Of the 19 patients in disease free group who were suspected disease recurrence with PET scanning, 7 positive PET images were found including 3 second primary malignancy and 4 non-cancer lesions. Two lymphoma cases with positive EBV-DNA value sequentially attacked before or after their NPC were diagnosed. Conclusions: EBV-DNA is a good marker of localized disease recurrence/metastasis after treatment for NPC but needs to be combined with imaging studies such as PET to monitor disease status. Citation Format: Cheng-Lung Hsu. Benefits of follow-up screening for Epstein Barr virus DNA in patients with localized nasopharyngial carcinoma . [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3550. doi:10.1158/1538-7445.AM2013-3550
COMPARISON OF TREATMENT PERSISTENCE IN THE REAL-WORLD USE OF NOVEL ORAL ANTICOAGULANTS AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
Authors: Cinira Lefevre, Michelle Johnson, Shuk-Li Collings, David Evans, Sebastian Kloss, Essra Ridha, Andrew Maguire, Bristol-Myers Squibb
Journal: Journal of the American College of Cardiology (2016)
P48 Haematopoietic but not mesenchymal stem cells contribute to the stromal microenvironment in cholangiocarcinoma and do not transdifferentiate into malignant bile ducts
Authors: A Robson, K Samuel, A Pellicoro, J Iredale, S Forbes
Journal: Gut (2010)

Aim  Cholangiocarcinoma (CC) is characterised by a pronounced inflammatory stroma consisting of tumour associated myofibroblasts, macrophages, immune cells and a modified extracellular matrix. Furthermore, in animal models of gastric cancer, reports have suggested that mesenchymal stem cells may contribute to the epithelial compartment of malignant tumours. The treatment options for CC are very limited. Therefore, an understanding of the source of tumour-associated cells in CC will inform therapy in the future.  Method  The matrix and cellular composition of the tumour niche was studied in humans and the thioacetamide (TAA) rat model of CC over 10 months. To investigate the cellular origin of the tumour and associated stroma, reconstituted wild type recipients of GFP+ bone marrow were administered TAA. Extra-hepatic derivation of cells was studied using dual immunoflourescence (GFP and CK19 (biliary epithelium), SMA (myofibroblasts), ED1, ED2 (macrophages) and MPO (neutrophils).) Persistent expression of GFP+ BM in control transplanted animals was confirmed by qPCR for Y-chromosome genomic DNA. Flow cytometry of blood, spleen and BM was performed to investigate GFP+ donor reconstitution of the haematopoietic compartment in recipient rats. BM of transplanted animals was cultured in mesenchymal stem cell (MSC) selective media and flow cytometry analysis for co-expression of stro-1 (a marker of MSC) and GFP was performed.  Results  In human and rat tissue a laminin rich extracellular matrix ensheathed neoplastic cholangiocytes. The tumour cellular microenvironment comprised of myofibroblasts, migratory macrophages (CD68+) and immune cells. In transplanted rats, GFP+ expression was persistent throughout the study period and chimerism was confirmed in BM, spleen and blood. GFP+ reconstitution of the haematopoietic and mesenchymal stem cell compartments was identified. Expression of stro1+GFP+ cultured cells was similar in transplanted animals and control GFP+ animals. In tumours, macrophages (ED1, ED2) and neutrophils (MPO) were overwhelmingly GFP+, whereas myofibroblasts (SMA) did not express GFP. Additionally, benign and malignant bile ducts were GFP negative.  Conclusion  A stereotypical niche forms around cholangiocarcinoma in developing and malignant lesions. The TAA rat model provides close correlation to human intrahepatic lesions with formation of a pronounced tumour microenvironment. We found no evidence of a BM-derived stem cell contribution to the epithelial component of cholangiocarcinoma. The haematopoietic but not the mesenchymal components of the tumour stroma were of BM origin.
Abdominal Aortic Aneurysm Detected Incidentally by Gallbladder Scintigraphy with Tc-99m Disofenin
Authors: REZA ABGHARI, SUSAN ERVINE, WENLIN FAN, VIVEK GUPTA, CARRIE HORST
Journal: Clinical Nuclear Medicine (2003)

Tc-99m disofenin imaging was performed in a 79-yearold man who had abdominal pain. The biliary scan findings were normal, but a large collection of radioisotope within the midabdomen was visible on the initial image, suggesting an abdominal aortic aneurysm. Subsequent computed tomographic (CT) imaging and an aortogram revealed a 5.8 × 5.0 cm infrarenal aortic aneurysm.
Abstract 1833: A large-scale synthetic lethal RNAi screening identifies unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma
Authors: Suhendan Ekmekcioglu, Yong Qin, Wuguo Deng, Elizabeth A. Grimm
Journal: Cancer Research (2012)

Abstract Metastatic melanoma is the most lethal form of skin cancer strongly associated with the inflammatory process by secreting high levels of proinflammatory cytokines and producing reactive oxygen and nitrogen species. Chronic inflammation is considered as a major factor to promote the tumor microenvironment in advantage of resistance to radiation, chemotherapy, and biotherapy for metastatic melanoma. CDDO-Me, a novel synthetic triterpenoid, has been shown to exert potent anti-inflammatory and antitumor activity by decreasing oxidative stress and the production of pro-inflammatory molecules, such as Nrf2 and iNOS, in several tumor models. CDDO-Me is presently under evaluation in clinical studies for chronic kidney disease and pancreatic cancer. Here, we used CDDO-Me as a primary agent to inhibit metastatic melanoma growth. In order to improve CDDO-Me response in melanoma cells, we utilized a large-scale synthetic lethal RNAi screen with 24,000 siRNAs targeting ∼6,000 human druggable genes to identify targets that when silenced would sensitize melanoma cells to CDDO-Me. Results from the screens identified twenty of siRNA pools that significantly potentiated the growth inhibitory effects of CDDO-Me in A375 cells. We selected five unique genes, GNPAT, SUMO1, SPUNT2, FLI1, and SSX1, which have not been addressed as drug targets in melanoma before, for target validation and functional analysis in four metastatic melanoma and control cell lines. Specific siRNA against each of these five genes could substantially sensitize four tested melanoma cells to CDDO-me by increasing the growth inhibition and induction of apoptosis, while treatment with nontarget siRNA resulted in no change compared to the treatment with CDDO-Me only. Further studies of downstream signaling revealed that these five genes involved in regulating melanoma cell proliferation and cell death. We identified for the first time that the levels of phosphorylated Erk1/2, Akt, GSK-2, and PRAS40, were dramatically decreased by individual siRNA against GNPAT, SUMO1, SPUNT2, FLI1, and SSX1. Our findings indicate that GNPAT, SUMO1, SPUNT2, FLI1, and SSX1 may play critical roles in synergy with inflammation pathways in modulating melanoma cell survival, which could serve as sensitizing targets to enhance CDDO-Me efficacy in melanoma. Supported by MDACC SPORE in Melanoma P50CA093459. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1833. doi:1538-7445.AM2012-1833
Vaccines May Help Debunk Secrets Of Cancer
Authors: J. Corliss
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Vaccines May Help Debunk Secrets Of Cancer Get access Julie Corliss Julie Corliss Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 11, 2 June 1993, Pages 850–851, https://doi.org/10.1093/jnci/85.11.850 Published: 02 June 1993
Early mucinous colorectal adenocarcinoma – mucosal type
Authors: E. Wolf, M. Vieth, H. Watanabe, E. Spuller, H. Leskowschek, C. Langner
Journal: Endoscopy (2010)

Colorectal cancer is defined by invasion through the muscularis mucosae into the submucosal layer. Mucosal changes with cytologic and architectural features of malignancy confined to the mucosa do not have a risk of metastasis, and according to the World Health Organization (WHO) classification these lesions are referred to as high grade intraepithelial neoplasia.
CARDIOVASCULAR EFFECTS OF HIGH-INTENSITY INTERVAL AEROBIC TRAINING COMBINED WITH STRENGTH EXERCISE IN PATIENTS WITH CHRONIC HEART FAILURE: A RANDOMIZED PHASE III CLINICAL TRIAL
Authors: Christine Chrysohoou, Athanasios Aggelis, George Tsitsinakis, Dimitris Tsiachris, Christos Pitsavos, Nikos Koulouris, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2015)
Removal Rates for Barbiturates Using Two Types of Peritoneal Dialysis
Authors: L. B. Berman, P. Vogelsang
Journal: New England Journal of Medicine (1964)

THE removal of poisons from the body by hemodialysis with an artificial kidney is now a well established procedure. Some of the principles and details have been reviewed by Schreiner.1 The number of potentially toxic substances is continually increasing, and, pari passu, the clinician's interest in finding ways to remove or neutralize them. The current popularity of peritoneal dialysis,2 with its relatively easy application,3 assures an interest in this technic as a means of removing poisons. Reports are available on the removal of barbiturates,3 , 4 salicylates,5 sodium chloride,6 boric acid7 and other materials. Yet very little quantitative information, particularly in . . .
SP0070 No ALL Night Sweats is Tuberculosis. Smoking is Bad for Your Health
Authors: A. Souto
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Smoking is bad for your health</h3> This is a 64 years old male with a four years history of rheumatoid arthritis. He was a heavy smoker (&gt;1ppd), and suffered from diabetes mellitus and chronic obstructive pulmonary disease. On his first visit, his DAS (ESR) was 5,6 and HAQ 1,6. The laboratory work showed anemia, elevated ESR and CRP. Radiographs of hands revealed narrowing of joint space and marginal erosions. He was initially treated with methotrexate (up to 22,5 mg) weekly and low doses of prednisone. Nine month later, Infiximab was added to the treatment because of lack of response. He improved and went into clinical remission with normalization of blood inflammatory parameters. Three years later, he developed dyspnea and dry cough. His musculo-skeletal exam was within normal limits with no evidence of articular inflammation. The laboratory work demonstrated anemia, and elevation of ESR and CRP. Infection including tuberculosis and "methotrexate lung" disease due to hypersensitivity reaction were excluded. The chest radiograph demonstrated a mass of 36 mm in the anterior segment of left upper lobe and pleural effusion. An open biopsy was obtained, and the pathology examination demonstrated a squamous cell carcinoma. Infliximab was discontinued and chemotherapy initiated. <h3>No all "night sweats" is tuberculosis</h3> This is a 55 years old female admitted to the ICU because fever, night sweats, dyspnea, cough, and hypotension. She had a ten years history of rheumatoid arthritis. At starting her articular symptoms, she was treated with methotrexate (up to 22,5 mg) weekly and low doses of prednisone. Due to lack of significant response, infliximab was added to the therapy. One year latter infliximab was discontinued and switched to adalimumab. She remained in clinical remission for eight years. On admission, she was tachycardic, with arterial hypotension, diaphoresis, and low systemic vascular resistance. Her physical examination showed generalized enlarged lymphonodes, and splenomegy. Her joint examination was irrelevant. The laboratory work demonstrated anemia, thrombocytopenia and elevation of ESR and CRP. Extensive investigations (cultures, PCR, and serology) excluded bacterial and viral infections. CT scan showed multiple thoracic and abdominal lymph nodes, and splenomegaly. Patient died in four days, and the postmortem examination revealed a no Hodgkin lymphoma with nodular sclerosis, and pulmonary embolism. These two cases raise important questions related to the risk of solid tumor and lymphoma in RA patients treated with TNF antagonists; Is the risk of tumors increased in RA patients? Is the overall risk of tumors increased in RA patients exposed to TNF antagonists? Is the risk higher in patients treated with anti-TNF monoclonal antibodies? Does the risk increase with the exposure? <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6223
AB0660 Serum coenzyme-q10 activity and oxidative status in patients with fibromyalgia
Authors: M. Bozkurt, P. oktayoğlu, D. uçar, S. Em, M. Caglayan, H. yuksel, I. Batmaz, M. A. Sariyildiz, K. Nas
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> In this study, we aimed to show the relationship between CoQ10 and fatigue symptoms of Fibromyalgia (FM). <h3>Methods</h3> A total of 40 patients diagnosed as primary FM according to the ACR criteria and 30 controls were included in the present study. All patients routine blood tests, erythrocyte sedimentation rate, total antioxidantstatus (TAS), total oxidativestatus (TOS) and Coenzyme Q10 (CoQ10) were evaluated. The patients were given the Fibromyalgia Impact Questionnaire (FIQ). Modified Fatigue Impact Scale (MFIS) weregiven in twogroupsandcompared. <h3>Results</h3> The mean ages of the patients and the control groups were 36.09±8.87 and 34.44±6.25, respectively. The age difference was not statistically significant (P = 0.266). The mean time of diagnosis of FM patients was 2.88 years and their average number of tender points was 14. The serum CoQ10 levels were significantly lower in FM patients when compared to the healthy control group (p=0.004). The serum TOS levels were higher in the FM group than in the control group (P&lt;0.05). The serum CoQ10 levels were negatively correlated with mean total score of MFIS (p=0.02, r=0.30), the mean scores for the 'physical' subscale of the MFIS (p=0.03, r=0.28), 'cognitive' (P = 0.02, r=0.30), VAS pain scores (p=0.00, r=0.38) and VAS fatigue scores (p=0.03, r=0.28). <h3>Conclusions</h3> CoQ10 deficiency may be responsible for the etiopathogenesis of fatigue of FM. Serum Coenzyme Q10 may be a marker for diagnosis and follow-up of patients with FM. <h3>Disclosure of Interest</h3> None Declared
Reflections on a Successful 2010
Authors: W. K. A. Yung
Journal: Neuro-Oncology (2010)

2010 was a year of change for Neuro-Oncology. Over the course of the year, the journal made major strides in helping the Society for Neuro-Oncology (SNO) meet its goal of advancing multidisciplinary research and education in the field of neuro-oncology. One means by which we made that possible was by moving to monthly publication by Oxford Journals, with about 1600 pages of text in about 125 scientific articles, up from 71 articles in 2009 and 46 in 2007, when the journal's current editorial team was assembled (and when, it should be noted, the journal was still just a quarterly publication). The focus has clearly been on growing the journal to meet the needs of its diverse readership and on ensuring it has the ability to reach into libraries and institutions worldwide.
Abstract 1277: Antigen-specific markers for paraneoplastic neurological syndromes obtained by proteomic analysis of patient immunoglobulins
Authors: Martijn M. vanDuijn, Peter Maat, Lennard J. Dekker, Theo M. Luider, Peter A. Sillevis Smitt
Journal: Cancer Research (2012)

Abstract In the antibody response, as occurs in antitumor immunity, germline sequences are rearranged and mutated to generate a sequence with specificity for an antigen. In earlier work, it was shown that the antigen specificity of immune sera from rats can be distinguished by the proteomic analysis of immunoglobulins. It is hypothesized that the sequence of the antigen binding sites converges to a similar subset in individuals exposed to a given antigen. We therefore tested the applicability of our approach in patients with Paraneoplastic Neurological Syndrome (PNS). In these patients, a tumor triggers a well-characterized auto-immune response against onconeural antigens expressed in tumor and the affected part of the nervous system. These antibodies serve as markers for both the underlying tumor and specific neurological syndromes. Sera of 60 patients with PNS associated with paraneoplastic antibodies were analysed: 20 anti-HuD (18 lung cancer), 20 anti-Yo (6 breast, 9 gynecological and one other cancer), 10 anti-amphiphysin (4 lung, one breast and one other cancer), and anti-CV2 (6 lung cancer) antibodies. Antigen-specific immunoglobulins were collected by affinity enrichment on beads coated with recombinant antigen. The antigen-specific immunoglobulins were digested with trypsin and analyzed by nano-LC and mass spectrometry. From the resulting dataset, peptides were selected that uniquely identified one of the patient groups, and the peptide sequence was deduced from fragmentation spectra. 28 specific and unique peptides were found; 0 specific for amphiphysin, 2 specific for CV2, 11 for HuD and 15 for Yo. Several marker peptide sequences showed homology to known immunoglobulin sequences, and no relations were found to other known proteins from the NCBInr protein database. The data show that immunoglobulin-derived biomarkers can indeed be found in samples from patients and can serve as early markers of cancer and auto-immunity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1277. doi:1538-7445.AM2012-1277
18F-FDG PET/CT Images in a Patient With Primary Chest Wall Tuberculosis Mimicking Malignant Tumor
Authors: Si-Yun Wang, Dong-Lan Luo, Gang Chen, Shu-Xia Wang
Journal: Clinical Nuclear Medicine (2015)

Solitary chest wall tuberculosis (TB) is rare. We report a case of primary chest wall TB in a 66-year-old woman involving the pleura and intercostal and erector spinae muscles. There was elevated FDG uptake in the right posterior chest wall. Surgery was performed, and pathology revealed inflammatory granuloma and caseous necrosis. Familiarity with 18F-FDG PET/CT images of chest wall TB could reduce possible misdiagnosis.
Abstract 5573: Discovery of potent oridonin derivatives for the treatment of breast cancer.
Authors: Yusong Zhang, Chunyong Ding, Zhengduo Yang, Haijun Chen, Lili Chu, Jia Zhou, Qiang Shen
Journal: Cancer Research (2013)

Abstract Oridonin, a diterpenoid derived from the herbal Rabdosia rubescens, has been reported to have antitumor effects on various types of cancer cells. However, its relatively low aqueous solubility and bioavailability have limited its development into clinical applications. Herein, we chemically modified oridonin and generated a series of novel analogues. We then employed MTT assay to detect their effects on cell growth and a number of new and potent molecules have been identified. Among them, compounds CYD-6-86 and CYD-6-92 significantly inhibited the proliferation of human breast cancer MDA-MB-231 and MCF-7 cells. Furthermore, both compounds induced enhanced apoptosis in a dose- and time-dependent fashion when compared with oridonin. Cell cycle analysis indicated that both CYD-6-86 and CYD-6-92 induced S phase arrest in MDA-MB-231 cells and G0/G1 phase arrest in MCF-7 cells, while oridonin induced G2/M phase arrest in MDA-MB-231 and MCF-7 cells. Consistent with oridonin, Western blot analysis showed that CYD-6-86 and CYD-6-92 inhibited the expression of NF-κB and Bcl-2, and increased expression of Bax and cleaved PARP. Intriguingly, compounds CYD-6-86 and CYD-6-92 have demonstrated to suppress the growth of adriamycin-resistant MCF-7 clone, while at the same dosage oridonin displayed no effect on these cells. Our findings suggest that these new analogues may be superior to the natural product oridonin to overcome the chemo-resistance, and have great potential to be developed as novel therapeutics for the treatment of breast cancer. Citation Format: Yusong Zhang, Chunyong Ding, Zhengduo Yang, Haijun Chen, Lili Chu, Jia Zhou, Qiang Shen. Discovery of potent oridonin derivatives for the treatment of breast cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5573. doi:10.1158/1538-7445.AM2013-5573